Enantioselective Synthesis of α,β-Disubstituted-β-amino Acids
摘要:
Highly diastereoselective and enantioselective addition of N-benzylhydroxylamine to imides 17 and 20-30 produces alpha,beta-trans-disubstituted N-benzylisoxazolidinones 19 and 31-41. These reactions proceed in 60-96% ee with 93-99% de's using 5 mol % of Mg(NTf2)2 and ligand 18. The product isoxazolidinones can be hydrogenolyzed directly to provide alpha,beta-disubstituted-beta-amino acids.
[EN] PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES<br/>[FR] INHIBITEURS DE JAK3 DE TYPE PYRROLOPYRIDAZINE ET LEUR UTILISATION POUR TRAITER LES MALADIES INFLAMMATOIRES ET AUTO-IMMUNES
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2012125887A1
公开(公告)日:2012-09-20
Disclosed are compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.
A versatile, synthesis of β-amino acids using the Nicholas reaction. I. Application to β-lactams of the carbapenem class
作者:Peter A. Jacobi、Wanjun Zheng
DOI:10.1016/s0040-4039(00)77630-1
日期:1993.4
Homochiral acetylenic acids of general structure 10, prepared using the Schreiber modification of the Nicholas reaction, have been converted to β-amino acid derivatives of type 11 by a two steps sequence involving Curtius rearrangement followed by oxidative cleavage of the acetylenic bond. Amino acid derivatives 11 are excellent precursors for β-lactams of the carbapenem class.
PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
申请人:Wrobleski Stephen T.
公开号:US20140005146A1
公开(公告)日:2014-01-02
Disclosed are compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.
Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
申请人:Wrobleski Stephen T.
公开号:US09221826B2
公开(公告)日:2015-12-29
Disclosed are compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.